The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2021 | HRQoL and frail patients with R/R multiple myeloma
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, gives an overview of her talk at EBMT 2021 on health-related quality-of-life (HRQoL) for frail patients with relapsed/refractory (R/R) multiple myeloma. Dr Mateos describes challenges associated with treating frail patients with R/R multiple myeloma, such as lenalidomide-refractoriness, and emphasizes the need to balance efficacy, tolerability and HRQoL. Dr Mateos also outlines potential therapies for this group of patients, highlighting pomalidomide plus dexamethasone with elotuzumab, bortezomib or isatuximab. A post-hoc analysis of the ICARIA-MM study (NCT02990338), conducted according to the frailty score, demonstrated that isatuximab plus pomalidomide and dexamethasone was equally effective in fit and frail patients with R/R multiple myeloma. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
